Personalized treatment of GBM guided by patient-derived organoid

We also developed a fast, efficient and complex culture system (IPTO: individualized patient-derived tumor organoid) which maintains the cellular diversity and molecular heterogeneity of human brain cancers. Patient derived tumor explant were cultured in iPSC derived cerebral organoid which allow generation of an organoid bank of several hundred of patient tumors. We showed that this model can host all tumors tested the central nervous system, including brain metastasis. Histology, epigenome and scRNA-seq analysis demonstrated that IPTOs model accurately maintain molecular and cellular features of parental tumors. Most importantly, we further demonstrated that the IPTO model predicts patient drug response in a perspective clinical study. The IPTO model represents a major breakthrough in preclinic modeling of human cancers, which provides a clear path toward personalized therapy of brain cancers. Currently efforts in the lab involves using IPTO for patient response prediction and targets discovery and validations.